Literature DB >> 27239912

[Endoscopic treatment of intestinal malrotation in newborns and infants].

Yu A Kozlov1, V A Novozhilov2, A A Rasputin3, G P Us3, N N Kuznetsova3, A Pakelchuk4.   

Abstract

AIM: To compare treatment of intestinal malrotation in newborns and infants using laparoscopy and laparotomy.
MATERIAL AND METHODS: For the period from January 2004 to December 2013 34 Ladd's procedures were performed. Children were divided into 2 groups by 17 patients: laparoscopic (group I) and open treatment (group II).
RESULTS: Both groups had similar demographic and other preoperative parameters. There were significant differences in duration of operation between both groups (61 vs. 70 minutes). Nutrition was initiated earlier after mini-invasive treatment (1.5 days vs. 3 days) and the time need for full enteral nutrition was also less (4.2 days vs. 6.9 days). Hospital-stay was shorter in group I (7.7 vs. 10.2 days). Number of early postoperative complications was similar in groups. Incidence of remote complications was higher in laparotomy group but the differences were not significant.
CONCLUSION: Our results showed that endoscopic correction of congenital anomalies of intestinal rotation provides better postoperative results than open surgery and can be widely used in young children.

Entities:  

Mesh:

Year:  2016        PMID: 27239912     DOI: 10.17116/hirurgia2016434-39

Source DB:  PubMed          Journal:  Khirurgiia (Mosk)        ISSN: 0023-1207


  2 in total

Review 1.  Open versus laparoscopic approach for intestinal malrotation in infants and children: a systematic review and meta-analysis.

Authors:  Vincenzo Davide Catania; Giuseppe Lauriti; Agostino Pierro; Augusto Zani
Journal:  Pediatr Surg Int       Date:  2016-10-05       Impact factor: 1.827

2.  Laparoscopic vs open Ladd's procedure for malrotation in neonates and infants: a propensity score matching analysis.

Authors:  Weike Xie; Zhongwen Li; Qi Wang; Lei Wang; Yongkang Pan; Chaoxiang Lu
Journal:  BMC Surg       Date:  2022-01-26       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.